IL2RA and neoplasm: Based on the literature on CD25+ Treg tumor content, patients with the following tumor types will be eligible: head and neck, non-small cell lung, gastric and esophageal, pancreas, bladder, renal, melanoma, triple negative breast, and ovarian cancers.